Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
What is the ticker symbol for Cingulate Inc.? What does CING stand for in stocks?
CING is the stock ticker symbol of Cingulate Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Cingulate Inc. (CING)?
As of Mon Dec 02 2024, market cap of Cingulate Inc. is 13.81 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of CING stock?
You can check CING's fair value in chart for subscribers.
Is Cingulate Inc. a good stock to buy?
The fair value guage provides a quick view whether CING is over valued or under valued. Whether Cingulate Inc. is cheap or expensive depends on the assumptions which impact Cingulate Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CING.